Objective: The objective of this article is to investigate why bladder cancer (BC) survival is worse in females using national cancer datasets. Patients and methods: All BC diagnoses since the year 2000 were identified from the National Cancer Data Repository (NCDR) using ICD-10 Code C67 (Bladder cancer T1-T4). Age-standardised relative survival rates for males and females diagnosed with BC between 2000 and 2010 were obtained from Public Health England. Results: Five-year relative survival of men with transitional cell carcinoma (TCC) BC (Code C67) was 61%, but in females was significantly less at 52%. One in four female BC (27%) patients are non-TCC, proportionately far more compared to 1:6 (16%) non-TCC BC in males. Five-year relative survival in non-TCC BC subtypes was notably reduced to 23% in females compared to 35% in men. Only 47% of patients with non-TCC BC receive surgical treatment compared to 82% for all BC. Conclusion: Relative survival from non-TCC BC is significantly less than the overall survival from TCC BC. Female patients with invasive BC have a worse survival than men. This is partly explained by the proportionately higher incidence of non-TCC BC in females, but women with TCC BC also have worse outcomes so other factors must contribute. Female gender should be recognised as an adverse risk factor in BC survival and influence management decisions.
Introduction
Bladder cancer (BC) is notable as one of the few cancers for which women have worse survival than men. The gender disparity seen in BC seems to be an international phenomenon, yet the mechanisms for poor survival in women are not completely understood. Globally, men have a three-fold higher incidence of BC, 1 but females have adverse survival. One-year survival for men diagnosed with BC is 72%-77% (2006-2010), but survival in females is significantly worse (58%-66%, 2006-2010) despite a better life expectancy overall. 2 In the United Kingdom (UK) population the age-standardised incidence of BC has declined in both sexes over the last 20 years, probably reflecting a changing lifestyle and reduced exposure to occupational risks. A change in BC coding was introduced in the year 2000 that removed non-invasive BC (pTa and carcinoma in situ) from the C67 code and this produced an apparent sharp decline in BC incidence that year. The number of deaths arising from non-invasive BC was minimal and so removing these cases reduced incidence of BC but not mortality and therefore one and five-year BC survival rates remained stable in both sexes.
The finding that BC is less common in females but survival is worse is atypical in the cancer landscape and has recently ignited further research. 3 Gender discrepancy in causation of BC, in particular less industrial exposure in women, is expected but we question whether differences in the epidemiology of BC histology might partly explain poor survival in women. Transitional cell (urothelial) carcinoma is diagnosed in 90% of BC. The remainder are non-transitional cell carcinomas (non-TCC) and include squamous cell, sarcoma, small cell and adenocarcinoma. It is not clear whether the epidemiology of these less-common types of BC is different compared to transitional cell carcinoma (TCC), and if so whether treatment options and outcomes differ accordingly. In this study we used national cancer datasets to investigate differences in the epidemiology of BC histology and the relationship to survival outcomes in women.
Methods
The National Cancer Intelligence Network (NCIN) and South West Public Health England (PHE) Knowledge and Intelligence Team (KIT) provided the data used in this study. Patients diagnosed with T1-T4 muscle-invasive BC between 2000 and 2010 were identified from the National Cancer Data Repository (NCDR) using International Classification of Diseases, 10th revision (ICD-10) Code C67. The analysis was restricted to exclude generic histology codes and so only cases that were TCC or non-TCC were included. The incidence rates prior to the year 2000 were excluded as comparison of data either side of this date is invalid due to the change in coding. PHE data provided age-standardised relative survival rates for men and women diagnosed with ICD-10 C67 BC between 2000 and 2010. Rates are standardised to the 1976 European standard population and per 100,000 of a sex-specific population. Survival data were used rather than mortality rates from non-TCC BC, as the morphology codes for mortality are not recorded on the Office for National Statistics (ONS) deaths database. All-cause survival and period survival for one and five years were calculated from the year 2000 onwards from NCDR datasets.
Results

Incidence
The age-standardised incidence rate (ASR) for BC in males between 2001 and 2004 showed a decreasing trend, but then remained stable until 2009, whereas in females a subtle decline was seen throughout the whole period.
Overall the ASR of all male BC was three times that of all female BC as expected ( Figure 1 ). The ASR of non-TCC BC remained stable throughout the decade 2000-2009 ( Figure 1 ). The incidence of non-TCC female BC is proportionally higher than male non-TCC BC (Figure 2 ). In men one in six have non-TCC BC compared to one in four females ( Table 1 ).
Survival
One-year and five-year survival for patients with TCC BC between 2000 and 2010 was 81% and 61.5% in males and 71.6% and 52.5% in females. Overall survival from TCC BC has not improved significantly in either sex over the period reviewed. The relative survival from non-TCC BC is significantly less than the overall survival from TCC BC. The same gender discrepancy is again true for non-TCC BC, and both one-and five-year survival for non-TCC BC is better in males (54.2% and 35%) than females (38.9% and 22.9%) ( Figure 3 ).
Treatment
Treatment records between 2007 and 2009 ( Table 2) showed that patients with non-TCC BC had surgical treatment in only 47% of cases, which included transurethral resection (TUR) of tumour and radical cystectomy (RC), compared to 82% of patients for all BC types. Overall patients with non-TCC BC had a lower recorded level of any treatment than the average for all BC (52% non-TCC, 84% all BC).
Discussion
This study investigates the relationship between epidemiology of BC histology and the gender disparity in BC survival. Females have worse BC survival than males and a causal explanation for this unusual trend remains incomplete. Women have a significant survival detriment both in TCC and non-TCC BC. The proportionally higher incidence of non-TCC BC in females may contribute to poor survival. Secondly, the treatment for non-TCC BC is limited and these patients are less likely to receive surgery. The gender disparity may be partly explained by a higher incidence of cystitis or chronic bladder inflammation in women, predisposing to non-TCC pathology as also seen in patients with neuropathic bladder. Richards et al. identified first presentation with urinary tract infection (UTI) as the greatest predictor for advanced disease and increased mortality risk in both genders, but UTI contributed to delayed diagnosis in women alone (58.9 versus 72.2 days, p < 0.001). 4 Misdiagnosis with UTI in women may account for delay in urological referral patterns, 5 but women with a history of cystitis also have worse outcomes overall. An Australian study of 6880 BC cases identified 16% of patients treated with cystectomy (16% men, 15% women). Women were 26% more likely to die post-cystectomy, yet those with a history of cystitis were 55% more likely to die compared to men with the same history. 6 Female gender is also implicated as the primary contributor to delay in referral time to cystectomy, 7 and women presenting with haematuria also experience delayed referral compared to men. 8 Women are found to present with more advancedstage BC, 9 and delay to diagnosis and referral may contribute to this. However, some studies demonstrate an inferior survival outcome in females even when compared to stage-matched male cohorts, 10 implying a more complex multi-factorial root cause.
Previous studies have also found that non-TCC BC is more common in females, although adjusting for histological type and stage did not completely explain adverse survival. 11 In a Spanish study 10% of tumours in females versus 3% in men were of 'other' histological types but only 23% of females compared to 54% of males received TUR alone and women were also five times more likely to receive non-standard treatment. 12 Non-TCC BC is likely to present with advanced-stage disease that may render radical treatment futile, a finding represented in our study where only 47% of patients with non-TCC BC received surgery. Data collection regarding treatment and histology was less well recorded by National Health Service (NHS) information systems during the study period and therefore more complete data from 2007 to 2009 and 2008 to 2012 were reviewed. We may expect all patients to have undergone surgery; however, coding did not include diagnostic biopsy, which would give a histological diagnosis but was not coded as a surgical treatment. Surgical treatment included TUR and RC, and the limited use of surgery in non-TCC bladder cancer suggests presentation with incurable disease rather than a reflection of under-treatment in this group.
Conclusion
The relative survival from non-TCC BC is significantly less than the overall survival from TCC BC, and treatment options are limited in this group. Our study has found that one in four females are diagnosed with non-TCC BC compared to one in six males. Given that survival in this histological subtype is much worse, we propose that this is a further factor contributing to overall poor survival in female BC. In conjunction with our findings, the research to date consistently infers that female gender should be recognised as an independent risk factor for adverse BC survival. It seems vital therefore to adapt our management of female BC accordingly and to consider a more aggressive course of action from the outset of diagnosis.
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